When asked about the astonishingly rapid development of the mRNA vaccine, Pfizer’s CEO, Dr. Albert Bourla, was clear: “It’s not that we were lucky. We were ready.”
What about you? Is your organization ready to make the impossible possible?
See how pharma leaders are unlocking the transformative potential of AI, medtech pioneers are delivering unprecedented social impact, and payers and providers are personalizing health care—all on a scale never seen before. | |
| | | The mRNA vaccine, developed in a record-breaking nine months, changed the course of history. Dr. Albert Bourla, Pfizer's chairman and CEO, describes the dramatic process that allowed his organization to believe that it could shoot for the moon and change the course of the pandemic. | | | | | | |
| Preparing for AI | | Artificial intelligence represents a paradigm shift in drug discovery and, ultimately, clinical development. The AI-fueled pipeline has been expanding at an annual rate of almost 40%. To maximize the efficiency boost from AI, biopharma companies should move quickly. | |
| Medical Devices and Technology | | |
| ESG: An essential component of the CEO agenda | | As a leading innovator of prosthetics, orthotics, and exoskeletons, Ottobock set out to also become the ESG leader in its field. By becoming a member of the UN Global Compact and measuring the socioeconomic benefits of its products, Ottobock is now one of the top ESG performers among 228 rated medtechs in Europe. | |
| Payers, Providers, Systems, and Services | | |
| The time for personalization is now | | Thanks to advances in technology, data, and analytics, truly personalized health care is possible on a scale that could not have been envisioned just a few years ago. There has never been a better time for health care organizations to develop sophisticated personalization capabilities. With the right preparation, organizations can see significant value in as little as six months. | |
